04-01-2009, 10:38 AM
|
#1
|
Senior Member
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
|
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer
International Journal of Clinical Oncology, 02/25/09 | Ono M et al. - In a trial to examine risk factors for development of brain metastasis in pts with HER2-overexpressing breast cancer who were treated with trastuzumab, it was shown that these pts had a high incidence of brain metastases (36.3%). Routine screening for brain metastases 1 yr after the start of trastuzumab treatment may be warranted in younger pts (≤50 yrs) who had recurrent breast cancer with liver metastases.
Methods - 204 pts with HER-2-overexpressing breast cancer who were treated with a trastuzumab-containing regimen were reviewed.
- Pts with clinical symptoms were diagnosed as having brain metastases when brain magnetic resonance imaging (MRI) or a computed tomography (CT) scan revealed positive findings for brain metastases.
- Median follow-up time of this cohort was 53.6 mos.
Results - Among the pts who received a trastuzumabcontaining regimen, 74 pts (36.3%) developed brain metastases.
- Median survival from diagnosis of brain metastases was 13.5 mos.
- Median time between beginning of trastuzumab treatment and diagnosis of brain metastases was 13.6 mos.
- Among pts with brain metastases, median overall survival period was 39 mos.
- A multivariate logistic regression analysis showed that age (≤50 yrs), recurrent breast cancer, and liver metastases were significant risk factors for development of brain metastases.
|
|
|
|